Hongyuan Pharmaceutical (301246.SZ) released its performance for the first three quarters, with net profit attributable to the parent company of 184 million yuan, a year-on-year increase of 16846.38%.

Zhitong Finance APP news, Hongyuan Pharmaceutical (301246.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 1.941 billion yuan, a year-on-year increase of 47.39%. Net profit attributable to shareholders of the listed company was 184 million yuan, a year-on-year increase of 16846.38%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 181 million yuan, a year-on-year increase of 842.38%.